Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00
CLDI.WS
CLDI.WS was delisted on the 17th of October, 2024.
Fund managers haven’t disclosed any holdings of CLDI.WS yet.
CLDI.WS Hedge Fund Activity: Q1 2025 in Review
0 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) for Q1 2025, worth a combined $0 — down 100% from $1.01K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of CLDI.WS and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Exos Asset Management, exiting entirely with an estimated $1.01K sold.
- 0 institutional investors held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) as of Q1 2025, down from 1 in Q4 2024.
- Funds reported $0 of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 stock for Q1 2025, down 100% quarter-over-quarter.
- 0 funds opened new Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 positions in Q1 2025 and 1 closed out, a net change of -1 holder.
- The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 seller in Q1 2025 was Exos Asset Management, an estimated $1.01K sold.
Based on aggregated 13F filings for Q1 2025.